新型光学光谱透射(OST)引导与传统疾病活动度引导治疗:早期类风湿关节炎达标治疗策略随机临床试验研究方案
本研究为多中心、双盲、非劣效性随机对照试验,纳入≥18岁新诊断、未使用改善病情抗风湿药(DMARD)的早期类风湿关节炎患者,随机分入DAS组或HandScan组,分别以ACR/EULAR 2011布尔缓解和HandScan缓解为目标指导治疗,主要结局为18个月时健康评估问卷(HAQ)评分,非劣效界值0.2,每组61例。
要点
- 研究比较HandScan引导的达标治疗与传统DAS引导治疗在早期RA中的疗效与成本效果。
- 主要结局为18个月HAQ评分,非劣效界值0.2,每组需61例(把握度80%,单侧P=0.05,脱落率10%)。
- 两组DMARD方案和治疗步骤完全相同,每月按预设步骤强化直至缓解,持续缓解3个月后逐渐减量。
核心结论
- 研究旨在验证HandScan引导的达标治疗(目标为HandScan缓解)在早期RA中是否不劣于且更具成本效果优于临床引导的达标治疗(目标为ACR/EULAR 2011布尔缓解)。
研究设计与样本
- 多中心、双盲、非劣效性随机对照试验,为期18个月。
- 纳入≥18岁、新诊断、未使用DMARD、符合ACR 2010分类标准的RA患者,随机分入DAS组或HandScan组,每组61例(把握度80%,单侧P=0.05,脱落率10%)。
主要发现
- 主要结局为18个月DMARD治疗后HAQ评分,组间非劣效界值为0.2。
- 次要结局包括成本效果差异和影像学关节损伤差异。
- HandScan利用光学光谱透射(OST)在手和腕部仅需1.5分钟即可客观评估RA疾病活动度。
关键数值与推荐
- 持续缓解定义为连续三个月持续存在的缓解,达到后DMARD治疗逐渐减量。
- 两组DMARD策略均每月按预设步骤强化直至达到缓解,且两组DMARD药物和治疗步骤完全相同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessment of disease activity is a critical component of tight-control, treat-to-target treatment strategies of rheumatoid arthritis (RA). Recently, the HandScan has been validated as a novel method for objectively assessing RA disease activity in only 1.5 min, using optical spectral transmission (OST) in hands and wrists. We describe the protocol of a randomized controlled clinical trial (RCT) to investigate whether HandScan-guided treatment aimed at 'HandScan remission' (HandScan arm) is at least as effective as and more cost-effective than clinically guided treatment aimed at ACR/EULAR 2011 Boolean remission (DAS arm). METHODS/DESIGN: The study is a multi-center, double-blind, non-inferiority RCT of 18 months duration. Patients ≥ 18 years with newly diagnosed, disease-modifying antirheumatic drug (DMARD)-naïve RA according to the ACR 2010 classification criteria, will be randomized to the DAS arm or the HandScan arm. The efficacy of the arms will be compared by evaluating Health Assessment Questionnaire (HAQ) scores (primary outcome) after 18 months of DMARD therapy, aimed at remission. The equivalence margin in HAQ scores between study arms is 0.2. Secondary outcomes are differences in cost-effectiveness and radiographic joint damage between treatment arms. The non-inferiority sample size calculation to obtain a power of 80% at a one-sided p value of 0.05, with 10% dropouts, resulted in 61 patients per arm. In both arms, DMARD strategy will be intensified monthly according to predefined steps until remission is achieved; in both arms DMARDs and treatment steps are identical. If sustained remission, defined as remission that persists consistently over three consecutive months, is achieved, DMARD therapy will be tapered. DISCUSSION: The study protocol and the specifically designed decision-making software application allow for implementation of this RCT. To test a novel method of assessing disease activity and comparing (cost-)effectiveness with the contemporary method in treat-to-target DMARD strategies in early RA patients. TRIAL REGISTRATION: Dutch Trial Register, NTR6388. Registered on 6 April 2017 ( NL50026.041.14 ). Protocol version 3.0, 19-01-2017.
引用
- Besselink NJ, Westgeest AAA, Klaasen R, et al. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. Trials. 2019. PMID: 30999969. doi:10.1186/s13063-019-3285-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。